At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.


French German Italian Portuguese Russian

Study of Hepatitis C Virus Outcomes After Treatment in Patients with Bleeding Disorders

Clinical Trial Title: 
Hepatitis C virus (HCV) outcomes after treatment with direct acting agents (DAA) in patients with bleeding disorders.
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Lisa Boggio, MD
Clinical Trial Protocol Description: 

Blood collection for HCV:

  • Six months after Baseline Visit
  • 1 year after Baseline
  • 18 Months after Baseline
  • 2 Years after Baseline
Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are a male or female with hemophilia or other bleeding disorder.
  • Are 25 years of age or older.
  • Have had exposure to any direct acting agents.
  • Have a diagnosis of HCV.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Contact Phone: 
(312) 942-3034
Contact Name: 
Lisa Boggio, MD